AR Isolate Bank – Year 2 – Customer Satisfaction Survey for CDC AR Isolate Bank Form Approved
OMB Control No.: 0920-1071
Exp. Date: 06/30/2018
REQUEST TO CUSTOMER—FIRST WAVE:
FROM: [email protected]
TO: POCs from order list
SUBJECT: 10-min survey about AR Isolate Bank
Dear AR Isolate Bank customer,
The FDA-CDC Antimicrobial Resistance Isolate Bank (AR Isolate Bank) launched in July 2015 and, as we approach our two-year mark, we would like to hear feedback on how it has provided value to your organization and how it can be improved.
Take the 10-minute survey here: [LINK]
The survey will be open until [DATE].
With your permission, we may contact you based on your responses to develop success stories that will be published on our website and in other CDC and FDA materials.
On behalf of CDC and FDA, we appreciate your participation in this survey. Your feedback will help us build a repository of the most useful isolates in the fight against antimicrobial resistance.
Best,
Jean B. Patel, PhD, D(ABMM)
Health Scientist, Antimicrobial Resistance Coordination and Strategy Unit
Centers for Disease Control and Prevention
Ribhi
M. Shawar, Ph.D, D(ABMM)
Branch Chief
General
Bacteriology and Antimicrobial Susceptibility Branch
CDRH/OIR
Division of Microbiology Devices
Food
and Drug Administration
[email protected]
REQUEST TO CUSTOMER—SECOND WAVE:
FROM: [email protected]
TO: POCs from order list
SUBJECT: How is the AR Isolate Bank doing?
Dear AR Isolate Bank customer,
This is a reminder that the FDA-CDC Antimicrobial Resistance Isolate Bank satisfaction survey will close [DATE].
Please take 10 minutes to complete the survey and provide feedback on how it has provided value to your organization and how it can be improved.
Take the survey now: [LINK]
With your permission, we may contact you based on your responses to develop success stories that will be published on our website and in other CDC and FDA materials.
On behalf of CDC and FDA, we appreciate your participation in this survey. Your feedback will help us build a repository of the most useful isolates in the fight against antimicrobial resistance.
Best,
Jean B. Patel, PhD, D(ABMM)
Health Scientist, Antimicrobial Resistance Coordination and Strategy Unit
Centers for Disease Control and Prevention
Ribhi
M. Shawar, Ph.D, D(ABMM)
Branch Chief
General
Bacteriology and Antimicrobial Susceptibility Branch
CDRH/OIR
Division of Microbiology Devices
Food
and Drug Administration
[email protected]
SURVEY HOSTED ON:
SurveyMonkey.com
INTRODUCTION:
Thank
you for providing feedback on the FDA-CDC Antimicrobial Resistance
Isolate Bank.
The purpose of the survey is to capture how
the AR Isolate Bank has provided value to customers and how it can be
improved.
The information gathered from this survey will
not be published and will only inform next steps of implementation.
PROPOSED QUESTIONS:
How did you first hear about the AR Isolate Bank? [can select only one]
CDC website
FDA website
CDC talk or presentation
FDA talk or presentation
FDA request or suggestion to support a regulatory submission
Colleague
Other: [open-ended]
What AR Isolate Bank panels did you/your organization order? Check all that apply.
How often have you/your organization ordered panels from the AR Isolate Bank? [can only select one]
1 occasion
2-5 occasions
6-9 occasions
10 occasions or more
How has your organization used the panels from the AR Isolate Bank? Check all that apply.
To develop (research, challenge, accelerate) a diagnostic device, test, or assay
To satisfy a specific request and/or support an application to FDA
To validate a diagnostic test for implementation in my laboratory
To develop (research, challenge, accelerate) an antibiotic
Other: [open-ended]
Based on your answer to Question #4, please provide more detail about how you have used the panels from the AR Isolate Bank. Please do not provide proprietary information. General descriptions for how the isolates helped improve process, increase product accuracy, meet organization priorities, add value, or support other AR strategies are appreciated. If you have not yet used the isolates, please explain how you intend to use them in the future. [open-ended]
Please take a moment to think about the AR Isolate Bank panels you received. Rate satisfaction with the following during your experience. [Likert scale: Very dissatisfied, Dissatisfied, Neither Dissatisfied nor Satisfied, Satisfied, Very satisfied, Not applicable]
Diversity of panels
Diversity of isolates available
Descriptions of panel organisms
Viability of organisms
Confirmatory testing in your lab corresponded to isolate description
Responsiveness of staff to questions or problems with panels or isolates
Please comment on ratings given above about satisfaction with panels. [open-ended]
CDC and FDA are working together to expand the AR Isolate Bank collection. What additional isolate panels or information would be valuable to you/your organization in the future? How can the current collection be improved? If you have ordered isolates from other organizations, what was most valuable about that experience? [open-ended]
Isolates of particular resistance patterns are often encountered in surveillance studies or from patients. If you encounter such isolates, would you be willing to provide isolates to be added to the AR Isolate Bank? If Yes, would you be willing to provide your contact information to CDC or FDA? If No, please provide your reason [open-ended]
No (provide reason below)
Yes, willing to provide isolates (provide your contact below)
Please take a moment to think about the AR Isolate Bank ordering process. Rate satisfaction with the following during your experience. [Likert scale: Very dissatisfied, Dissatisfied, Neutral, Satisfied, Very satisfied, Not applicable]
Information provided with the isolates (i.e., MIC results and interpretation, sequencing information)
Order instructions provided on the website
Responsiveness of staff
Duration of entire process (from initial order to delivery)
Please comment on ratings given above about satisfaction with panels. [open-ended]
CDC and FDA are working to improve the AR Isolate Bank website. What other information in content or structure would you like to see added or improved? How can the current website be improved? [open-ended]
Which option below best describes your organization? [can select only one]
Academic
Commercial diagnostic company
Commercial laboratory
Federal agency
Hospital or clinic
Pharmaceutical company
Public health laboratory
Other: [open-ended]
If a new isolate is added to the AR Isolate Bank, would you like CDC to send you an automated email letting you know the new product is available? [can select only one]
Yes, I would like to receive an email update.
No, I check the site often and know what is new.
No, I get enough email updates.
No, I already have what I need from the AR Isolate Bank and don’t need other isolates.
Can we contact you for additional information? To improve the AR Isolate Bank overall and develop success stories, we would like to contact some customers for more information about their experience. We will NOT publish responses provided in this survey or confidential, proprietary information. [can select only one]
If yes, please provide your name and email address. [open-ended]
Public
reporting burden of this collection of information is estimated to
average 10 minutes per response, including the time for reviewing
instructions, searching existing data sources, gathering and
maintaining the data needed, and completing and reviewing the
collection of information. An agency may not conduct or sponsor,
and a person is not required to respond to a collection of
information unless it displays a currently valid OMB Control Number.
Send comments regarding this burden estimate or any other aspect of
this collection of information, including suggestions for reducing
this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton
Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA 0920-1071
| File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| Author | Katy Capers |
| File Modified | 0000-00-00 |
| File Created | 2021-01-22 |